CRISPR Therapeutics
CRSP

$57.92

0.61%

Market Cap: 4.92B

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

Employees: 407

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 19 analysts

0

News positive %

of 25 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

21% more call options, than puts

Call options by funds: $256M | Put options by funds: $212M

17% more capital invested

Capital invested by funds: $3.48B [Q4 2023] → $4.05B (+$577M) [Q1 2024]

14% more repeat investments, than reductions

Existing positions increased: 154 | Existing positions reduced: 135

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 4 (+0) [Q1 2024]

0% less funds holding

Funds holding: 465 [Q4 2023] → 464 (-1) [Q1 2024]

0.46% less ownership

Funds ownership: 69.91% [Q4 2023] → 69.45% (-0.46%) [Q1 2024]

1% less first-time investments, than exits

New positions opened: 68 | Existing positions closed: 69

See Fund Rankings

Research analyst outlook

19 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$48

17%

downside

Avg. target

$82

42%

upside

High target

$112

93%

upside

19 analyst ratings

12 positive

63%

6 neutral

32%

1 negative

5%

Needham Gil Blum	52%upside $88	Buy Reiterated	27 Jun 2024
Piper Sandler Edward Tenthoff	81%upside $105	Overweight Reiterated	17 Jun 2024
Needham Gil Blum	52%upside $88	Buy Reiterated	17 Jun 2024
Citigroup Yigal Nochomovitz	45%upside $84	Buy Maintained	23 May 2024
Oppenheimer Jay Olson	64%upside $95	Outperform Maintained	10 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 25 articles about CRSP published over the past 30 days

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.

CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

Zacks Investment Research

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

3 Gene Editing Stocks Shaping the Future of Medicine

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

The Motley Fool

3 Monster Stocks in the Making to Buy Right Now

CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.

3 Monster Stocks in the Making to Buy Right Now

3 Gene Editing Stocks That Could Grow Your Wealth

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.

3 Gene Editing Stocks That Could Grow Your Wealth

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition

Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition

24/7 Wall Street

Add These 5 Hot Biotech Stocks In July

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

Zacks Investment Research

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

The Motley Fool

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dollar portfolio of products; Casgevy marks CRISPR Therapeutics' first product approval.

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

See News Rankings